Objective : This was permed to evahmte the m hic changes in breast density tlrat were associated with hormone repboement >l vpy{HR) ipi`Korean postmenopausal women.
Materials and h : In this retrospective study, 294 postmenopausal women were classified as the four groups according to the regimen of HRT: a daily treatment of tibolone 2.5 mg(n=119), conjugated equine estrogen(CEE) 0.625 nig/medroxyprogesterone(MPA) 2.5 mg(n=93), CEE 0.625 mg only(n=40) or raloxifene 60 mg(n--42), and they were compared with the corWl group of postmenopausal non-HRT users(n=36). Mammography was performed at baseline and aft l year of treatment; and the incidence of changes in mammographic density was evaluated and compared among them.
Results : There were no significant -differences in age, panty, age at menopause, years after menopause, weight, height, and body mass index(BMI) among the groups. The risk of an increase in mammographic density after 1 year of treatment was significantly higher in CEE/MPA group(24/93, 25.8%), compared with tibolone(14/119, 11.8%) and raloxifene(1/42, 2.4%) gronps(p4005).
Conclusion : This study showed that the changes in mammographic breast density related to postmenopausal HRT were dependent on the regimen of HRT. The continuous administration of progestogen as a component of the combined HRT seems to affect the breast density significantly.
|